[go: up one dir, main page]

AR037402A1 - Derivados de 4-(oxadiazol-3-il)-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 4-(oxadiazol-3-il)-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR037402A1
AR037402A1 ARP020104492A ARP020104492A AR037402A1 AR 037402 A1 AR037402 A1 AR 037402A1 AR P020104492 A ARP020104492 A AR P020104492A AR P020104492 A ARP020104492 A AR P020104492A AR 037402 A1 AR037402 A1 AR 037402A1
Authority
AR
Argentina
Prior art keywords
group
trifluoromethoxy
dialkylamino
trifluoromethyl
cyano
Prior art date
Application number
ARP020104492A
Other languages
English (en)
Inventor
Frederic Galli
Odile Leclerc
Alistair Lochead
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of AR037402A1 publication Critical patent/AR037402A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de fórmula general (1), útil tratamiento o prevención de desórdenes relacionados con disfunción de receptores nicotinicos, en especial a nivel SNC. Reivindicación 1: Compuesto que responde a la fórmula general (1), en la cual: R representa un grupo cicloalquilo C3-6 o un grupo fenilo eventualmente sustituido por uno o varios grupos elegidos entre un átomo de halógeno, un grupo alquilo C1-6, alcoxi C1-6, nitro, amino, dialquilamino C1-3, trifluorometoxi, trifluorometilo, ciano , hidroxi, metilendioxi, o un grupo piperidin-1-ilo, o 4-morfolinilo, o pirrolidin-1-ilo, o azetidin-1-ilo, o azepin-1-ilo, o piridinilo, o tienilo, opirazinilo, o furilo, o benzofurilo, o benzotienilo, o indolilo, o pirimidinilo, o isoxazolilo, o fenoxazinilo, o dibenzofurilo o dibenzotienilo o pirrolilo, o naftilo, pudiendo cada uno de esos grupos ser eventualmente sustituido por uno o varios grupos elegidos entre un átomo de halógeno, un grupo alquilo C1-6, alcoxi C1-6, trifluorometoxi, trifluorometilo, nitro, ciano, hidroxi, amino, dialquilamino C1-3, o cicloalquilamino C3-8, en estado de base o de sal de adición con un ácido.
ARP020104492A 2001-11-23 2002-11-22 Derivados de 4-(oxadiazol-3-il)-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica AR037402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0115153A FR2832712B1 (fr) 2001-11-23 2001-11-23 Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR037402A1 true AR037402A1 (es) 2004-11-10

Family

ID=8869705

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104492A AR037402A1 (es) 2001-11-23 2002-11-22 Derivados de 4-(oxadiazol-3-il)-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica

Country Status (10)

Country Link
US (1) US7022697B2 (es)
EP (1) EP1451188B1 (es)
JP (1) JP4477876B2 (es)
AR (1) AR037402A1 (es)
AT (1) ATE290534T1 (es)
AU (1) AU2002361326A1 (es)
DE (1) DE60203197T2 (es)
FR (1) FR2832712B1 (es)
TW (1) TW200303312A (es)
WO (1) WO2003044019A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7220741B2 (en) 2002-09-30 2007-05-22 Neurosearch A/S 1,4-diazabicycloalkane derivatives, their preparation and use
US7223753B2 (en) 2002-11-11 2007-05-29 Neurosearch A/S Diazabicyclic biaryl derivatives
DE60309740T2 (de) * 2002-11-11 2007-03-29 Neurosearch A/S 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zu ihrer herstellung und therapeutical verwendung
EP1581213A4 (en) * 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
BRPI0407216A (pt) 2003-02-27 2006-01-24 Neurosearch As Derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição
JP2007520526A (ja) * 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ コリン作動性受容体モジュレーターとしてのジアザビシクロアリール誘導体
EP1713810B1 (en) * 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7662812B2 (en) 2005-02-16 2010-02-16 Neurosearch A/S Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors
AU2006239418A1 (en) * 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
WO2006130493A2 (en) 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
CA2632642A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
AU2007267174B2 (en) 2006-05-30 2012-08-02 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
CA2667545A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
US20100280015A1 (en) * 2007-08-17 2010-11-04 Neurosearch A/S Noval 1,4-diaza-biclo[3.2.2]nonyl oxadiazolyl derivatives useful as nicotinic acetylcholine receptor ligands
ES2673016T3 (es) 2008-11-19 2018-06-19 Forum Pharmaceuticals Inc. Tratamiento de los síntomas negativos de la esquizofrenia con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
WO2010063784A1 (en) * 2008-12-04 2010-06-10 Neurosearch A/S Novel diaza-bicyclononyl-phenyl derivatives and their medical use
WO2010084185A1 (en) 2009-01-26 2010-07-29 Neurosearch A/S Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use
US20110319397A1 (en) * 2009-01-27 2011-12-29 Neurosearch A/S Novel n-oxides of furanyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
CN102802620A (zh) * 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
WO2011073296A1 (en) 2009-12-18 2011-06-23 Neurosearch A/S Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators
EP3604302A1 (en) 2010-05-17 2020-02-05 Forum Pharmaceuticals Inc. Preparation of crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
WO2012139925A1 (en) 2011-04-15 2012-10-18 Neurosearch A/S Labelled and un-labelled methyl-pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226000A (en) * 1987-09-10 1991-06-25 Merck Sharp & Dohme Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
FR2786770B1 (fr) 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
FR2809731B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
FR2832712A1 (fr) 2003-05-30
AU2002361326A1 (en) 2003-06-10
JP4477876B2 (ja) 2010-06-09
WO2003044019A1 (fr) 2003-05-30
ATE290534T1 (de) 2005-03-15
EP1451188B1 (fr) 2005-03-09
DE60203197D1 (de) 2005-04-14
US20040266757A1 (en) 2004-12-30
JP2005510525A (ja) 2005-04-21
DE60203197T2 (de) 2006-02-02
TW200303312A (en) 2003-09-01
FR2832712B1 (fr) 2004-02-13
US7022697B2 (en) 2006-04-04
EP1451188A1 (fr) 2004-09-01

Similar Documents

Publication Publication Date Title
AR037402A1 (es) Derivados de 4-(oxadiazol-3-il)-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica
AR037403A1 (es) Compuestos, ligandos, receptores nicotinicos, utiles para el tratamiento o para la prevencion de desordenes relacionados con una disfuncion de receptores nicotinicos, particularmente a nivel del sistema nervioso central
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
BRPI0615111B8 (pt) composto, composição farmacêutica, e, uso do composto
CO4820390A1 (es) Quinazolinas substituidas y bioisoesteres como inhibidores de la tirosina cinasa c-erb b- 2
ATE469888T1 (de) Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
AR035763A1 (es) Compuestos derivados de diamidas heterociclicas, metodo para controlar una plaga de invertebrados y composicion que lo comprende
ATE381542T1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
DE602005005167D1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
ES2192520T3 (es) Composicion farmaceutica.
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
RU95117585A (ru) ПРОИЗВОДНЫЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
ATE413388T1 (de) Muskarin antagonisten
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
ATE432922T1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2, 4ütriazole als viruzide
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
EA200600829A1 (ru) Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона
EA200500191A1 (ru) Кристаллический 2,5-дион-3-(1-метил-1h-индол-3-ил)-4-[1-(пиридин-2-илметил)пиперидин-4-ил]-1h-индол-3-ил]-1h-пирролмоногидрохлорид
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics

Legal Events

Date Code Title Description
FA Abandonment or withdrawal